The aryl hydrocarbon receptor is associated with monocytic AML and innate immune resistance reversible with an AHR inhibitor
Year: 2025
Type: article
Language: en
Topic: Toxic Organic Pollutants Impact
Authors and affiliations:
raw_author_name: Jennifer N. Saultz
raw_affiliation_strings: Division of Hematology/Medical Oncology, Oregon Health & Science University, Portland, OR, United States
Knight Cancer Institute, Oregon Health & Science University, Portland OR, United States
raw_author_name: Daniel Bottomly
raw_affiliation_strings: Knight Cancer Institute, Oregon Health & Science University, Portland OR, United States
raw_author_name: Faith Burns
raw_affiliation_strings: Knight Cancer Institute, Oregon Health & Science University, Portland OR, United States
raw_author_name: Kaelan Byrd
raw_affiliation_strings: Knight Cancer Institute, Oregon Health & Science University, Portland OR, United States
raw_author_name: Yoko Kosaka
raw_affiliation_strings: Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR, United States
Knight Cancer Institute, Oregon Health & Science University, Portland OR, United States
raw_author_name: Bernhard Alber
raw_affiliation_strings: Knight Cancer Institute, Oregon Health & Science University, Portland OR, United States
raw_author_name: Daniel Chandra
raw_affiliation_strings: Division of Hematology/Medical Oncology, Oregon Health & Science University, Portland, OR, United States
Knight Cancer Institute, Oregon Health & Science University, Portland OR, United States
raw_author_name: Stephen E. Kurtz
raw_affiliation_strings: Knight Cancer Institute, Oregon Health & Science University, Portland OR, United States
raw_author_name: Guang Fan
raw_affiliation_strings: Molecular Pathology and Molecular Diagnostics Laboratories, Knight Diagnostic Laboratories, Oregon Health & Science University, Portland, OR, United States
raw_author_name: Andy Kaempf
raw_affiliation_strings: Biostatistics Shared Resource (BSR) Knight Cancer Institute, Oregon Health & Science University, Portland, OR, United States
raw_author_name: Nicola Long
raw_affiliation_strings: Knight Cancer Institute, Oregon Health & Science University, Portland OR, United States
raw_author_name: Marta Sanchez-Martin
raw_affiliation_strings: IKENA Oncology, Boston, MA, United States
raw_author_name: Lei Wang
raw_affiliation_strings: IKENA Oncology, Boston, MA, United States
raw_author_name: Karen McGovern
raw_affiliation_strings: IKENA Oncology, Boston, MA, United States
raw_author_name: Dan S. Kaufman
raw_affiliation_strings: Division of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA, United States
raw_author_name: Shannon K. McWeeney
raw_affiliation_strings: Division of Bioinformatics and Computational Biology, Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, OR, United States
Division of Oncological Sciences Oregon Health & Science University, Portland, OR, United States
Knight Cancer Institute, Oregon Health & Science University, Portland OR, United States
raw_author_name: Brian J. Druker
raw_affiliation_strings: Division of Hematology/Medical Oncology, Oregon Health & Science University, Portland, OR, United States
Knight Cancer Institute, Oregon Health & Science University, Portland OR, United States
raw_author_name: Jeffrey W. Tyner
raw_affiliation_strings: Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, OR, United States
Knight Cancer Institute, Oregon Health & Science University, Portland OR, United States
raw_author_name: Evan F. Lind
raw_affiliation_strings: Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, OR, United States
Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR, United States
Knight Cancer Institute, Oregon Health & Science University, Portland OR, United States